In ultrasound, small companies are few and far between; here, capital equipment companies rarely get venture backing, and the diversity of clinical segments that ultrasound serves requires sellers to have both large technical and marketing resources. But small companies like SonoSite, with new high-performing and lower-cost hand-held devices hope to disrupt the big-company, radiology-oriented status quo. The small companies are carving out some new non-radiology markets--guidance for catheter insertion, emergency medicine, Ob/Gyn and primary care--by positioning ultrasound as a new kind of triage tool.
By Mary Stuart
It was early Sunday morning and the emergency room of the Highland General Hospital, an inner-city teaching hospital in Oakland,...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Plus deals involving Takeda/Innovent, Genentech/Ventus, Sanofi/EVOQ, Novo Nordisk/Sumitomo, Lisata/Catalent, Boehringer Ingelheim/Accent, BI/Molcure, tech transfer agreements and more.
The Paris-based group is paying €350m upfront to get hold of Marseille-headquartered ImCheck's acute myeloid leukemia candidate.
Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.
Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.
Excellence, innovation and deal-making across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2025, held in Tokyo on 21 October.
Drug development in China was a discussion topic at the BioFuture conference as the country’s R&D investments begin to deliver first-in-class medicines.
Despite announcing sales growth that is currently weathering the storm of one of its biggest losses of exclusivity and a spin-off of its orthopedic division, J&J’s stock price weakened after its earnings announcement. Investors probably wanted more visibility on MFN.
